Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course.

[1]  F. Gottrand,et al.  Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis , 2018, Hepatology communications.

[2]  E. Loftus,et al.  Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease , 2018, Alimentary pharmacology & therapeutics.

[3]  P. Rosenthal,et al.  Mo1446 - Initial Results of the Wuppsc Study – Prospective Multicenter Withdrawal of Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis (PSC) , 2018 .

[4]  T. Karlsen,et al.  Primary sclerosing cholangitis - a comprehensive review. , 2017, Journal of hepatology.

[5]  F. Gottrand,et al.  The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration , 2017, Hepatology.

[6]  M. Manns,et al.  Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. , 2017, Gastroenterology.

[7]  M. Zheng,et al.  Immunosuppressive Agents for the Treatment of Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis , 2017, Digestive Diseases.

[8]  M. Jonas,et al.  The Natural History of Primary Sclerosing Cholangitis in Children: A Large Single-Center Longitudinal Cohort Study , 2016, Journal of pediatric gastroenterology and nutrition.

[9]  J. Raes,et al.  Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD , 2016, Gut.

[10]  A. Lohse,et al.  Unmet clinical need in autoimmune liver diseases. , 2015, Journal of hepatology.

[11]  K. Boberg,et al.  Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  R. Chapman,et al.  Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. , 2013, Journal of hepatology.

[13]  T. Karlsen,et al.  Primary sclerosing cholangitis , 2001, The Lancet.

[14]  P. Rosenthal,et al.  Validation and modification of simplified diagnostic criteria for autoimmune hepatitis in children. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  E. Björnsson,et al.  Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[16]  G. Gores,et al.  Diagnosis and management of primary sclerosing cholangitis , 2010, Hepatology.

[17]  K. Lindor,et al.  High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis , 2009, Hepatology.

[18]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[19]  R. Chapman,et al.  High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. , 2006, Journal of hepatology.

[20]  K. Boberg,et al.  High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. , 2005, Gastroenterology.

[21]  N. LaRusso,et al.  High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.

[22]  K. Lindor.  Ursodiol for Primary Sclerosing Cholangitis , 1997 .

[23]  J. Bircher,et al.  Ursodeoxycholic acid–induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis , 1990, Hepatology.

[24]  P. Galle,et al.  Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes , 1990, Hepatology.

[25]  P. Gane,et al.  Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid , 1990, Hepatology.